Q-Med AB: Invitation to Q1 report conference call Time: Tuesday, April 29, 2008 at 1.30 p.m. CET. To join the conference: Swedish dial in number: + 46 (0)8 505 201 14 UK dial in number: +44 (0)20 7162 0125 Q-Med participants: Bengt Ågerup, CEO Alexander Kotsinas, CFO Madelene Sandgren, Director Investor Relations and Corporate Communications The press release for Q-Med AB's Q1 report will be released approximately 12.30 on April 29, 2008. The slide presentation will be available at: www.q-med.com/Investors/Presentations A recorded version of the presentation will be available for seven working days on tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 79 32 42. Queries should be addressed to: Madelene Sandgren, Director Investor Relations and Corporate Communications, Tel: + 46 (0)70 974 90 15 Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46(0)18-474 90 00. Fax: +46(0)18-474 90 01. E-mail: info@q-med.com. Web: www.q-med.com. In USA, Q-Med AB's affiliate is the wholly-owned subsidiary Q-Med Scandinavia, Inc.
Q-Med AB: Invitation to Q1 report conference call
| Source: Q-Med AB
Attachments
